Ethosomes may be effective carrier system for transdermal delivery

Ethosomes are ethanolic nanovesicles that possess abundant amount of ethanol in its core which provides fluidity to the lipid bilayers and thus by this effect, improves the delivery of molecules into the deep skin layers. These vesicles are capable of enclosing both hydrophilic and lipophilic drugs.

Various preclinical and clinical reports on drugs delivered via ethosomes have been highlighted in this article which suggests that these nanocarriers can be employed for drug targeting via transdermal route.

Antimicrobials such as clotrimazole, terbinafine, acyclovir, stavudine, etc have been discussed; these drugs show improved preclinical and clinical results. Anti-inflammatory drugs like thiocolchicoside, curcumin and piroxicam have also depicted with improved anti-inflammatory action.

Drugs acting on CNS viz vinpocetine, valsartan, ropinirole, ligustrazine phosphate, upon loading into ethosomes exhibited enhanced percutaneous absorption/ bioavailability. Several other drugs like alfuzosin hydrochloride, repaglinide, testosterone propionate, enoxaparin, etc also exhibited better penetration, and fluorescence intensity.

Several in vitro and in vivo permeability analysis delineated the enhancement of permeability. In vivo confocal laser scanning microscopy depicted the quantity as well as depth of penetrability via ethosomes.

Patents on ethosomal transdermal drug delivery have suggested that these nanocarriers can be employed effectively with enhanced penetration and drug diffusion.

Further, safety and toxicity issues have also been raised. Ethosomes have demonstrated no adverse skin reactions in clinical trials with drugs. Post marketing data has also revealed no other adverse reactions, thus, proving them to be safe and effective for drug delivery.

Binary, composite ethosomes, transethosomes are recently developed ethosomal carriers have gained considerable attention as drug delivery vehicles in the past few years and could prove to be an effective carrier system for transdermal delivery.

Ethosomal-based transdermal drug delivery could eventually become an important accession for therapeutics offered to several diseases in the future.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
First-generation antihistamine drugs could increase seizure risk among young children